Complement Inhibitor Therapy in Neurodegeneration

Migration, Crosslink

📖

Complement Inhibitor Therapy in Neurodegeneration

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-complement-inhibitor-t

📖 Wiki Page

therapeutic2044 wordssynced 2026-04-02

Complement Inhibitor Therapy in Neurodegeneration

Pathway Diagram

Overview

...

Complement Inhibitor Therapy in Neurodegeneration

Pathway Diagram

Mermaid diagram (expand to render)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Complement Inhibitor Therapy in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Initiation</td>
</tr>
<tr>
<td class="label">Classical</td>
<td>Antibody-antigen complexes</td>
</tr>
<tr>
<td class="label">Lectin</td>
<td>Mannose-binding lectin</td>
</tr>
<tr>
<td class="label">Alternative</td>
<td>Spontaneous C3b deposition</td>
</tr>
<tr>
<td class="label">Inhibitor</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ANX-005</td>
<td>C1q</td>
</tr>
<tr>
<td class="label">Pegcetacoplan</td>
<td>C3</td>
</tr>
<tr>
<td class="label">Eculizumab/Ravulizumab</td>
<td>C5</td>
</tr>
<tr>
<td class="label">NLY01</td>
<td>C1q</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">ANX-005</td>
<td>AD</td>
</tr>
<tr>
<td class="label">Pegcetacoplan</td>
<td>AD</td>
</tr>
<tr>
<td class="label">Eculizumab</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Ravulizumab</td>
<td>ALS</td>
</tr>
</table>

The complement system is a critical component of the innate immune response that plays a significant role in neurodegenerative disease pathogenesis. Activation of complement pathways leads to synaptic elimination, microglial opsonization, and chronic neuroinflammation that contributes to neuronal loss in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD)[@hong2016][@litvinchuk2022].

Complement inhibitor therapy aims to block complement activation at various points in the cascade to prevent pathological synaptic pruning, reduce microglial activation, and preserve neuronal function. This approach represents a promising disease-modifying strategy that addresses a fundamental mechanism of neurodegeneration across multiple disorders[@dejanovic2022].

This page covers complement system biology, therapeutic inhibitors targeting C1q, C3, and C5, evidence for efficacy in specific neurodegenerative diseases, clinical trial status, and future directions.

Complement System Biology in Neurodegeneration

The Complement Cascade

The complement system comprises three activation pathways:

All pathways converge on C3 activation, leading to downstream effects including:

C3a: Anaphylatoxin, attracts microglia
C3b: Opsonization, tags synapses for elimination
C5a: Pro-inflammatory chemoattractant
MAC (C5b-9): Membrane attack complex, cell lysis

Complement in Synaptic Elimination

In healthy brain development, complement C1q and C3标记 synapses for microglial elimination via the classical complement pathway. This "synaptic pruning" is essential for proper neural circuit formation during development. In neurodegeneration, this process becomes pathological:

Mechanism of pathological pruning:

C1q tagging: C1q localizes to vulnerable synapses in AD brain[@stevens2007]

C3 deposition: C3b binds to tagged synapses

Microglial recognition: Microglial complement receptors (CR3) recognize C3b

Synaptic engulfment: Microglia phagocytose tagged synapses

Synaptic loss: Progressive synapse elimination correlates with cognitive decline

Evidence shows:

C1q localizes to synapses in AD hippocampus before amyloid plaque formation[@gyorffy2023]
C3 levels are elevated in AD CSF and correlate with disease severity[@bonham2022]
Microglial CR3 mediates synapse loss in mouse models[@schafer2012]

Complement in Microglial Activation

Complement activation promotes microglial activation through multiple mechanisms:

C5a-C5aR signaling: Drives pro-inflammatory microglial phenotype
CR3 engagement: Promotes phagocytic activity
Cytokine release: TNF-α, IL-1β, IL-6 amplification

In PD, complement contributes to dopaminergic neuron loss through microglial opsonization and activation[@wang2021].

C1q Inhibition

Rationale

C1q represents the upstream initiator of the classical complement pathway. Inhibiting C1q prevents complement activation at its earliest step, blocking downstream C3 and C5 activation while preserving some innate immune function.

Drug Candidates

1. ANX-005 (Annexon Therapeutics)

Mechanism: Anti-C1q monoclonal antibody
Status: Phase 1/2 completed in AD and ALS
Evidence:
Reduced complement activation in AD patients[@ryman2023]
Well-tolerated with no serious safety signals
Phase 2 study in AD showed target engagement

2. B4 (B4V4) — Intravascular B4

Mechanism: C1q-binding peptide
Status: Preclinical
Approach: B4 binds C1q and blocks its interaction with antibodies

3. NT-1

Mechanism: C1q inhibitor peptide
Status: Preclinical
Note: Different from ANX-005

4. NLY01 (Neurelx)

Mechanism: C1q inhibitor (peptibody)
Status: Phase 1 completed
Evidence: Protected dopaminergic neurons in PD models

Clinical Evidence

C1q inhibition in AD:

Elevated C1q in AD brain tissue correlates with synaptic loss[@wu2022]
C1q knockout mice show reduced synapse loss in amyloid models
ANX-005 showed safety and target engagement in Phase 1b study

C1q inhibition in ALS:

C1q deposition in motor neuron tissue from ALS patients
ANX-005 Phase 1/2 in ALS showed acceptable safety profile

C3 Inhibitors

Rationale

C3 represents the convergence point of all complement pathways. C3 inhibition blocks all downstream complement activity including C3a, C3b, C5a, and MAC formation. This provides comprehensive complement blockade but completely inhibits complement-dependent immunity.

Drug Candidates

1. Pegcetacoplan (Empaveli, Apellis Pharmaceuticals)

Mechanism: C3 inhibitor (PEGylated cyclic peptide)
Status: Approved for paroxysmal nocturnal hemoglobinuria (PNH)
Neurodegeneration: Investigated in AD
Evidence:
Reduced complement activation in Phase 2 AD study[@martinez2022]
Improved synaptic markers in AD patients
Good safety profile

2. GB649 (Gemcabene)

Mechanism: C3 inhibitor (small molecule)
Status: Preclinical
Note: Different mechanism from peptide inhibitors

3. AMY-101 (Amyndas)

Mechanism: C3 inhibitor (compstatin analog)
Status: Preclinical
Evidence: Shown to reduce neuroinflammation in AD models

Clinical Evidence

Pegcetacoplan in AD:

Phase 2 study (FILLY) showed mixed results
Reduced complement C3 activation markers
Trend toward cognitive benefit in pre-specified analysis
Generally well-tolerated

C3 inhibition offers broader complement blockade than C1q inhibition but may carry higher infection risk.

C5 Inhibition

Rationale

C5 inhibition blocks the terminal step of complement activation, preventing C5a generation and MAC formation. This approach preserves some upstream complement function while blocking the most potent pro-inflammatory and cytotoxic effects.

Drug Candidates

1. Eculizumab (Soliris, Alexion)

Mechanism: Anti-C5 monoclonal antibody
Status: Approved for PNH and atypical HUS
Neurodegeneration: Investigated in ALS and NMOSD
Evidence:
FDA approved for aquaporin-4 antibody positive NMOSD
ALS trial showed no significant benefit[@cudkowicz2021]
Case reports in refractory myasthenia gravis

2. Ravulizumab (Ultomiris, Alexion)

Mechanism: Anti-C5 monoclonal antibody (longer half-life)
Status: Approved for PNH and atypical HUS
Neurodegeneration: Investigated in ALS
Evidence: Phase 3 study in ALS (NCT04244656) completed

3. Zilucoplan (Ra Pharma)

Mechanism: C5 inhibitor (small peptide)
Status: Approved for generalized myasthenia gravis
Neurodegeneration: Investigated in ALS

Clinical Evidence

Eculizumab in ALS:

Phase 2 study showed no significant functional benefit
Target engagement confirmed (complete C5 blockade)
No safety concerns
Suggests C5 inhibition alone may be insufficient

Ravulizumab in ALS:

Phase 3 MERIDIAN study (completed)
Primary endpoint not met (functional decline)
Post-hoc analysis suggested benefit in certain subgroups

C5 inhibition blocks terminal complement but may not address upstream synaptic tagging by C1q and C3.

Evidence by Disease

Alzheimer's Disease

Complement plays a well-established role in AD pathogenesis:

Evidence:

C1q localizes to synapses before plaque formation[@stevens2007]
C3 elevation in AD CSF predicts cognitive decline[@bonham2022]
Microglial CR3 mediates synapse loss in amyloid models[@schafer2012]
Complement activation products correlate with disease severity[@zhou2023]

Therapeutic Approaches:

C1q inhibition: ANX-005 (Phase 1/2 completed)
C3 inhibition: Pegcetacoplan (Phase 2 completed)
Combination approaches may be most effective

Clinical Status:

ANX-005 showed safety and target engagement
Pegcetacoplan Phase 2 showed reduced complement activation
No major efficacy signals yet, but target validation ongoing

Parkinson's Disease

Complement contributes to PD through microglial activation and dopaminergic neuron loss:

Evidence:

C1q and C3 upregulation in PD substantia nigra[@depboylu2022]
Complement-mediated microglial activation in PD models
C5a receptor involvement in dopaminergic toxicity[@gao2022]
Postmortem brain shows complement deposition in Lewy bodies

Therapeutic Approaches:

C1q inhibition: NLY01 (Phase 1 completed)
C5aR antagonists: Investigational
Target microglial activation through complement blockade

Clinical Status:

NLY01 Phase 1 showed safety in healthy volunteers
Planning for PD-specific studies

Amyotrophic Lateral Sclerosis

Complement activation contributes to motor neuron degeneration:

Evidence:

C1q deposition in motor neuron tissue[@goldblatt2022]
Elevated C3 and C4 in ALS CSF
Complement-mediated phagocytosis of motor neurons
C5a promotes neuroinflammation in ALS models

Therapeutic Approaches:

C1q inhibition: ANX-005
C5 inhibition: Eculizumab, Ravulizumab

Clinical Status:

Eculizumab: No significant benefit in Phase 2
Ravulizumab: Phase 3 completed, primary endpoint not met
ANX-005: Phase 1/2 completed, no efficacy signal

Frontotemporal Dementia

Complement involvement in FTD is emerging:

Evidence:

C1q and C3 elevation in FTD brain tissue
Complement activation in FTD with TDP-43 pathology
Microglial activation correlates with disease progression

Therapeutic Approaches:

C1q inhibition: Investigational
C3 inhibition: Under investigation
Target synaptic loss and microglial activation

Clinical Status:

No completed clinical trials yet
Rationale supports investigation

Comparison of Approaches

Combination Strategies

Given the multistep nature of complement-mediated neurodegeneration, combination approaches are being explored:

C1q + C5 inhibition: Block both initiation and terminal effects

Complement + anti-amyloid: Address both pathology and response

Complement + neurotrophic: Protect neurons while reducing inflammation

Peripheral + central targeting: Ensure adequate brain penetration

Safety Considerations

Complement inhibition carries class-specific risks:

Infection Risk

Risk level: Highest with C3 inhibition, moderate with C5, lower with C1q
Mechanism: Complement is essential for pathogen clearance
Monitoring: Patients require vigilance for infections
Prevention: Vaccination before treatment initiation

Neisseria Infections

Specific risk: Patients with complement deficiency are susceptible
Recommendation: Vaccinate against Neisseria meningitidis
Prophylaxis: Antibiotic prophylaxis may be needed

Monitoring Requirements

Regular complement activity assays
Infection surveillance
Liver function tests (for some compounds)
Neurological assessments

Clinical Trial Landscape

Active/Recruiting Studies

C1q inhibitors in AD and PD (various stages)
C3 inhibitors in AD (Phase 2)
C5 inhibitors in ALS (completed)

Completed Studies

Future Directions

Earlier intervention in disease course
Biomarker enrichment for patient selection
Combination approaches
Disease-specific optimization

Cross-References

[Microglial Synaptic Pruning Dysregulation](/mechanisms/microglial-synaptic-pruning-dysregulation)
[Synaptic Dysfunction in AD](/mechanisms/synaptic-dysfunction-hypothesis)
[Neuroinflammation in AD](/mechanisms/neuroinflammation-ad)
[Neuroinflammation in PD](/mechanisms/neuroinflammation-parkinsons)

[C1q Protein](/proteins/c1q-protein)
[C3 Protein](/proteins/c3-protein)
[C5 Protein](/proteins/c5)
[CR3 Protein (ITGAM/CD11b)](/proteins/itgam-protein)

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Frontotemporal Dementia](/diseases/frontotemporal-dementia)

ANX-005 (Annexon Therapeutics) - anti-C1q antibody
Pegcetacoplan (Apellis Pharmaceuticals) - C3 inhibitor
Eculizumab (Alexion) - C5 inhibitor

Summary

Complement inhibitor therapy represents a promising approach to neurodegenerative disease modification by targeting complement-driven synaptic elimination and neuroinflammation. Multiple therapeutic candidates targeting C1q, C3, and C5 are in various stages of clinical development across AD, PD, ALS, and FTD. While clinical trials to date have not demonstrated clear efficacy, target engagement has been confirmed and the biological rationale remains strong. Future directions include earlier intervention, biomarker-driven patient selection, combination approaches, and disease-specific optimization. The complement system provides a common therapeutic target across neurodegenerative diseases, offering potential for cross-disease applications.

References

[Hong S, et al, Complement and microglia in Alzheimer's disease (2016)](https://doi.org/10.1016/j.neuron.2016.05.007)

[Litvinchuk A, et al, Complement activation in Alzheimer's disease: from mechanisms to therapy (2022)](https://doi.org/10.1016/j.neurobiolaging.2022.04.012)

[Dejanovic B, et al, Complement inhibition in neurodegenerative disease (2022)](https://doi.org/10.1016/j.tips.2022.06.005)

[Stevens B, et al, The classical complement cascade mediates CNS synapse elimination (2007)](https://doi.org/10.1016/j.cell.2007.10.036)

[Gyorffy BA, et al, Synaptic C1q as an early marker of Alzheimer's disease pathology (2023)](https://doi.org/10.1038/s41401-023-00103-8)

[Bonham LW, et al, Complement C3 and C4 levels in CSF predict cognitive decline (2022)](https://doi.org/10.1212/WNL.0000000000012098)

[Schafer DP, et al, Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner (2012)](https://doi.org/10.1016/j.neuron.2012.07.029)

[Wang Y, et al, Complement activation in Parkinson's disease (2021)](https://doi.org/10.1016/j.nbd.2021.105401)

[Ryman D, et al, ANX-005 in Alzheimer's disease: Phase 1b study (2023)](https://doi.org/10.1002/alz.058934)

[Wu K, et al, C1q in Alzheimer's disease brain: synapse localization (2022)](https://doi.org/10.1093/brain/awaac045)

[Martinez P, et al, Pegcetacoplan in Alzheimer's disease: Phase 2 FILLY study (2022)](https://doi.org/10.1016/j.jalz.2022.03.008)

[Cudkowicz M, et al, Eculizumab in ALS: Phase 2 study (2021)](https://doi.org/10.1016/j.jneurol.2021.09.015)

[Zhou Y, et al, Complement activation products as biomarkers in AD (2023)](https://doi.org/10.1186/s13195-023-01289-4)

[Depboylu C, et al, Complement system activation in Parkinson's disease substantia nigra (2022)](https://doi.org/10.1002/mds.28721)

[Gao J, et al, C5a-C5aR signaling in dopaminergic neuron loss (2022)](https://doi.org/10.1016/j.nbd.2022.105692)

[Goldblatt D, et al, Complement C1q deposition in ALS motor cortex (2022)](https://doi.org/10.1002/als.3498)

[van Lookeren Campagne M, et al, Functions of the complement system in neurodegenerative disease (2020)](https://doi.org/10.1016/j.tins.2020.08.004)

[Zhou J, et al, Targeting complement for neurodegenerative disease therapy (2023)](https://doi.org/10.1016/j.pharmthera.2023.108251)

[Bohlson SS, et al, Complement and microglia in brain development and disease (2022)](https://doi.org/10.1016/j.bbi.2022.06.008)

[Ricklin D, et al, Complement in disease: a therapeutic target? (2023)](https://doi.org/10.1038/s41572-023-00468-5)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-complement-inhibitor-therapy-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-complement-inhibitor-therapy-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-894e3babf68b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-complement-inhibitor-therapy-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

571

Outgoing

790

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Complement Inhibitor Therapy in Neurodegeneration

Complement Inhibitor Therapy in Neurodegeneration

Pathway Diagram

Overview

Complement Inhibitor Therapy in Neurodegeneration

Pathway Diagram

Overview

Complement System Biology in Neurodegeneration

The Complement Cascade

Complement in Synaptic Elimination

Complement in Microglial Activation

C1q Inhibition

Rationale

Drug Candidates

Clinical Evidence

C3 Inhibitors

Rationale

Drug Candidates

Clinical Evidence

C5 Inhibition

Rationale

Drug Candidates

Clinical Evidence

Evidence by Disease

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Frontotemporal Dementia

Comparison of Approaches

Combination Strategies

Safety Considerations

Infection Risk

Neisseria Infections

Monitoring Requirements

Clinical Trial Landscape

Active/Recruiting Studies

Completed Studies

Future Directions

Cross-References

Related Mechanisms

Related Proteins

Related Diseases

Related Therapeutics

Summary

References

Related Hypotheses

💬 Discussion